Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.[10] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[10] It is given by intravenous infusion.[10]
Combination of | |
---|---|
Nivolumab | Programmed death receptor-1 (PD-1) blocking antibody |
Relatlimab | Lymphocyte activation gene-3 (LAG-3) blocking antibody |
Clinical data | |
Trade names | Opdualag |
AHFS/Drugs.com | Monograph |
MedlinePlus | a622037 |
License data |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
|
The combination was approved for medical use in the United States in March 2022,[10][12] and in the European Union in September 2022.[11] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[13][14]
The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.[10][11]
In July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opdualag, intended for the treatment of melanoma.[11][15] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[15] Opdualag was approved for medical use in the European Union in September 2022.[11][16]
In January 2024, the National Institute for Health and Care Excellence (NICE) recommended nivolumab-relatlimab) as a first-line treatment of advanced melanoma in patients aged 12 years and older.[17]
{{cite web}}
: CS1 maint: archived copy as title (link)